Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation
Microbial Biotechnology · 2025
DOI: 10.1111/1751-7915.70109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Yutong Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Engineering Science, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: SARS-CoV-2, Escherichia coli, Single-Domain Antibodies, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
The COVID‐19 pandemic has caused unparalleled impacts on global social dynamics, healthcare systems and economies, highlighting the urgent need for effective interventions to address current challenges and future pandemic preparedness. This study introduces a novel virus neutralisation platform based on SimCells (~1 μm) and mini‐SimCells (100–200 nm), which are chromosome‐free and non‐replicating bacteria from an LPS‐free Escherichia coli strain (ClearColi). SimCells and mini‐SimCells were engineered to display nanobodies on their surface, specifically targeting the receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike protein – a critical immunogenic fragment essential for viral entry into host cells. It was demonstrated that nanobody‐expressing SimCells achieved over 90% blocking efficiency against synthesised RBD from both the original Wuhan and the B.1.351 (Beta) variant using competitive enzyme‐linked immunosorbent assay (ELISA) assay. More importantly, live virus neutralisation assays demonstrated that NB6 nanobody‐presenting mini‐SimCells effectively neutralised the live SARS‐CoV‐2 Victoria variant with an IC50 of 2.95 × 10 9 ± 1.40 × 10 8 mini‐SimCells/mL. Similarly, VE nanobody‐presenting mini‐SimCells effectively neutralised the B.1.351 (Beta) variant of the SARS‐CoV‐2 virus with an IC50 of 5.68 × 10 9 ± 9.94 × 10 8 mini‐SimCells/mL. The mini‐SimCells successfully protected Vero cells, a cell line derived from the kidney of an African green monkey, from infection by the live virus of SARS‐CoV‐2 and its variants. These results suggest that SimCell‐based neutralisation offers a promising strategy for the prevention and treatment of SARS‐CoV‐2, and potentially other viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Engineering Science, University of Oxford, Oxford, UK.
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
- Oxford Suzhou Centre for Advanced Research (OSCAR), University of Oxford, Suzhou Industrial Park, Suzhou, Jiangsu, China.
- Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
- Department of Medicine, University of Oxford, Oxford, UK.
ORCID-Profile: Wei E Huang
Förderung
- Engineering and Physical Sciences Research Council
Zitieren
APA
Yin, Y., Liu, C., Ji, X., Wang, Y., Mongkolsapaya, J., Screaton, G. R., Cui, Z., & Huang, W. E. (2025). Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70109
Vancouver
Yin Y, Liu C, Ji X, Wang Y, Mongkolsapaya J, Screaton GR, et al. Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70109
BibTeX
@article{Yin2025,
author = {Yin, Yutong and Liu, Chang and Ji, Xianglin and Wang, Yun and Mongkolsapaya, Juthathip and Screaton, Gavin R and Cui, Zhanfeng and Huang, Wei E},
title = {Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation},
journal = {Microbial Biotechnology},
year = {2025},
doi = {10.1111/1751-7915.70109}
}
EUVIMED